Histamine dihydrochloride oral - EpiCept Corporation
Alternative Names: HD-OLatest Information Update: 02 Oct 2021
At a glance
- Originator Maxim Pharmaceuticals
- Class Antiepileptic drugs; Antimigraines; Antineoplastics; Antiparkinsonians; Antipsychotics; Antivirals; Behavioural disorder therapies; Ethylamines; Imidazoles; Neuroprotectants; Small molecules
- Mechanism of Action Histamine H2 receptor agonists; Oxygen radical formation antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alcoholic hepatitis; Hepatitis C; Non-alcoholic steatohepatitis
Most Recent Events
- 09 Jan 2006 Maxim Pharmaceuticals has been acquired and merged into EpiCept Corporation
- 23 Jun 2004 Histamine dihydrochloride oral is available for licensing and development (http://www.maxim.com/)
- 21 May 2004 Data presented at the Digestive Disease Week-2004 (DDW-2004) have been added to the Liver Disorders pharmacodynamics section